Cytomegalovirus risk factors in renal transplantation with modern immunosuppression

Transplant Infectious Disease

Volumn 12, Issue 6, 2010, Pages 480-488

  Bataille, S ^a   Moal, V ^a   Gaudart, J ^b   Indreies, M ^a   Purgus, R ^a   Dussol, B ^a,b   Zandotti, C ^c   Berland, Y ^a,b   Vacher Coponat, H ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Cytomegalovirus; Immunosuppressive regimen; Kidney transplantation; Preemptive therapy; Prophylaxis; Renal failure

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE ACETATE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COLD ISCHEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; AZATHIOPRINE; CHEMOPREVENTION; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 78650119705     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00533.x     Document Type: Article

References (28)

1. Preitsaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5 (2): 218-227.
2. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3 (Suppl 2): 1-5.
3. Ricart MJ, Malaise J, Moreno A, et al.; the Euro-SPK Study Group, Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005; 20 (Suppl 2): ii25-ii32, ii62.
4. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; 2: CD003774.
5. Reichsig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87 (3): 436-444.
6. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-2007.
7. Sagedal S, Nordal K, Hartmann A, et al. Preemptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18 (9): 1899-1908.
8. Reischig T, Jindra P, Svecovac M, Kormunda S, Opatrny K, Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006; 36 (2): 146-151.
9. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261 (24): 3607-3609.
10. Paya CV, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections (2nd edn). Philadelphia: Lippincott, Williams & Wilkins, 2003: 298-325.
11. Fishman JA. Infection in solid organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
12. Hjelmesæth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47 (9): 1550-1556.
13. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5 (12): 2894-2900.
14. Humar A, Gillingham K, Payne WD, Sutherland DE, Matas AJ. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000; 70 (2): 310-313.
15. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16 (6): 1758-1774.
16. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66 (1): 329-337.
17. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8 (5): 975-983.
18. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 (2): 262-274.
19. Huurman VAL, Kalpoe JS, Van De Linde P, et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006; 29 (4): 842-847.
20. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007; 7 (5 Pt 2): 1359-1375.
21. Womer KL, Kaplan B. Recent developments in kidney transplantation - a critical assessment. Am J Transplant 2009; 9 (6): 1265-1271.
22. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009; 11 (3): 195-202.
23. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129 (1): 125-137.
24. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8 (10): 2111-2118.
25. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research (2nd edn). New York: Chapman & Hall/CRC, 2007.
26. San Juan R, Aguado JM, Lumbreras C, et al.; RESITRA Network of the Spanish Study Group of Infection in Transplantation. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 (7): 875-882.
27. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3 (5): 1487-1493.
28. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55 (4): 851-857.